Ensysce Biosciences, Inc.
About Ensysce Biosciences, Inc.
Ensysce Biosciences, Inc. develops innovative chemistry-based therapies focused on pain management and reducing risks of prescription opioid abuse. Its TAAP platform creates prodrugs designed to improve patient care for chronic pain while limiting abuse, and the MPAR platform adds overdose protection when combined with TAAP. The company is advancing clinical candidates such as PF614-MPAR-102 and has also worked with nafamostat for infection treatment and overdose protection. It maintains operations in La Jolla, California, with investor relations at ir.ensysce.com and corporate site at ensysce.com.
Investors
Not disclosed in the source filing. Form D filings do not list investors — StreetZero surfaces them from news where available.
Key highlights
- Raised $77.2 million via private placement tied to Cy Biopharma acquisition.
- Completed multi-year $15 million NIDA grant with final $5.3 million installment.
- Advancing PF614-MPAR-102 clinical study with full enrollment of Part 2 announced.
- TAAP and MPAR platforms target prescription opioid abuse and overdose reduction.
- Post-deal cash position improved from $0.7 million to approximately $31 million.
Ask StreetZero about Ensysce Biosciences, Inc.
Put our AI to work on this deal.
Similar companies
Other Other Health Care deals, ranked by Signal.
Source document & SEC filing
The source SEC filing and the cached document are available to members only. Sign in to view and download them.
Sign in to view the filing Create free account